<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02545933</url>
  </required_header>
  <id_info>
    <org_study_id>IIS 53376</org_study_id>
    <nct_id>NCT02545933</nct_id>
  </id_info>
  <brief_title>Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor</brief_title>
  <acronym>VORA-PRATIC</acronym>
  <official_title>Adjunctive Vorapaxar Therapy in Patients With Prior Myocardial Infarction Treated With New Generation P2Y12 Receptor Inhibitors Prasugrel and Ticagrelor (VORA-PRATIC): A Prospective, Randomized, Pharmacodynamic Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor represents the&#xD;
      standard of care for the long-term secondary prevention of atherothrombotic events in&#xD;
      patients with myocardial infarction (MI). However, rates of ischemic recurrences remain high,&#xD;
      which may be in part due to the fact that other platelet signaling pathways, such as&#xD;
      thrombin-induced platelet aggregation, continue to be activated. Vorapaxar is a&#xD;
      protease-activated receptor (PAR)-1 inhibitor, which exerts potent inhibition of&#xD;
      thrombin-mediated platelet aggregation. It is approved for clinical use by the Food and Drug&#xD;
      Administration for the reduction of thrombotic cardiovascular events in patients with a&#xD;
      history of MI or with peripheral arterial disease. However, to date clinical trial experience&#xD;
      with vorapaxar has been almost exclusively with the P2Y12 receptor inhibitor clopidogrel and&#xD;
      the effects of vorapaxar in combination with antiplatelet therapy including prasugrel or&#xD;
      ticagrelor, is largely unexplored. Further, the role of vorapaxar as part of a dual&#xD;
      antithrombotic treatment regimen, in addition to a novel P2Y12 receptor inhibitor, with&#xD;
      withdrawal of aspirin, represents another important area of clinical interest as it has the&#xD;
      potential to maximize ischemic protection while reducing the risk of bleeding. The proposed&#xD;
      prospective, randomized, parallel-design, open label, study conducted in a real world&#xD;
      clinical setting of post-MI patients will aim to assess the pharmacodynamic effects of&#xD;
      vorapaxar in addition to antiplatelet therapy with a novel P2Y12 receptor inhibitor&#xD;
      (prasugrel or ticagrelor) with and without aspirin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor represents the&#xD;
      standard of care for the long-term secondary prevention of atherothrombotic events in&#xD;
      patients with myocardial infarction (MI). The novel P2Y12 receptor inhibitors prasugrel and&#xD;
      ticagrelor are characterized by more prompt, potent, and predictable antiplatelet effects&#xD;
      compared with clopidogrel and are associated with a greater reduction of ischemic events in&#xD;
      acute coronary syndrome patients. However, rates of ischemic recurrences remain high, which&#xD;
      may be in part due to the fact that other platelet signaling pathways, such as&#xD;
      thrombin-induced platelet aggregation, continue to be activated. Vorapaxar is a novel, orally&#xD;
      active, competitive and slowly reversible protease-activated receptor (PAR)-1 inhibitor,&#xD;
      which exerts potent inhibition of thrombin-mediated platelet aggregation. It is approved for&#xD;
      clinical use by the Food and Drug Administration for the reduction of thrombotic&#xD;
      cardiovascular events in patients with a history of MI or with peripheral arterial disease. A&#xD;
      large-scale clinical trial showed that the use of vorapaxar (2.5 mg once/daily) in addition&#xD;
      to standard antiplatelet therapy (including aspirin and a P2Y12 receptor inhibitor) was&#xD;
      effective in the secondary prevention of recurrent thrombotic events in patients with&#xD;
      previous atherothrombosis, in particular in patients with prior MI, at the expense of an&#xD;
      increase in major bleeding. However, to date clinical trial experience with vorapaxar has&#xD;
      been almost exclusively with the P2Y12 receptor inhibitor clopidogrel and the effects of&#xD;
      vorapaxar in combination with state-of-the-art antiplatelet therapy in the post-MI setting,&#xD;
      including prasugrel or ticagrelor, is largely unexplored. This may indeed represent a&#xD;
      limitation for the uptake of vorapaxar in modern day clinical practice where these agents are&#xD;
      being more broadly utilized. Further, the role of vorapaxar as part of a dual antithrombotic&#xD;
      treatment regimen, in addition to a novel P2Y12 receptor inhibitor, with withdrawal of&#xD;
      aspirin, represents another important area of clinical interest as it has the potential to&#xD;
      maximize ischemic protection while reducing the risk of bleeding. The proposed prospective,&#xD;
      randomized, parallel-design, open label, study conducted in a real world clinical setting of&#xD;
      post-MI patients will aim to assess the pharmacodynamic effects of vorapaxar in addition to&#xD;
      antiplatelet therapy with a novel P2Y12 receptor inhibitor (prasugrel or ticagrelor) with and&#xD;
      without aspirin. Pharmacodynamic assessments will be performed at multiple time points and&#xD;
      with different assays exploring multiple pathways of platelet aggregation. Exploratory&#xD;
      assessments on the safety of such approach will also be evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Actual">January 2020</completion_date>
  <primary_completion_date type="Actual">May 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal Platelet Aggregation</measure>
    <time_frame>30 days</time_frame>
    <description>The primary end point of our study is the comparison of maximal platelet aggregation measured by light transmittance aggregometry using CAT (collagen-ADP-TRAP) between DAPT and DAPT plus vorapaxar after 30 days of treatment.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>DAPT plus vorapaxar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin plus prasugrel or ticagrelor plus vorapaxar 2.5mg od</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prasugrel/ticagrelor plus vorapaxar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prasugrel or ticagrelor plus vorapaxar 2.5mg od</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DAPT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin in addition to prasugrel or ticagrelor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel</intervention_name>
    <description>Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)</description>
    <arm_group_label>DAPT</arm_group_label>
    <arm_group_label>DAPT plus vorapaxar</arm_group_label>
    <arm_group_label>Prasugrel/ticagrelor plus vorapaxar</arm_group_label>
    <other_name>Effient</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vorapaxar</intervention_name>
    <description>Vorapaxar will be administered at the dose of 2.5mg once daily</description>
    <arm_group_label>DAPT plus vorapaxar</arm_group_label>
    <arm_group_label>Prasugrel/ticagrelor plus vorapaxar</arm_group_label>
    <other_name>Zontivity</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Aspirin will be administered at the dose of 81mg once daily</description>
    <arm_group_label>DAPT</arm_group_label>
    <arm_group_label>DAPT plus vorapaxar</arm_group_label>
    <other_name>ASA (acetylsalicylic acid)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)</description>
    <arm_group_label>DAPT</arm_group_label>
    <arm_group_label>DAPT plus vorapaxar</arm_group_label>
    <arm_group_label>Prasugrel/ticagrelor plus vorapaxar</arm_group_label>
    <other_name>Brilinta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Patients with a prior MI within the previous 2 weeks to 12 months.&#xD;
&#xD;
          2. On DAPT with low-dose aspirin (81mg od) and either prasugrel (10mg od) or ticagrelor&#xD;
             (90mg bid) as per standard-of-care for at least 2 weeks.&#xD;
&#xD;
          3. Free from bleeding and ischemic events after the index MI event.&#xD;
&#xD;
          4. Age between 18 and 75 years old.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. History of stroke, transient ischemic attack, or intracranial hemorrhage.&#xD;
&#xD;
          2. Active pathological bleeding, history of bleeding events or increased risk of&#xD;
             bleeding.&#xD;
&#xD;
          3. Known severe hepatic impairment.&#xD;
&#xD;
          4. Age &gt;75 years.&#xD;
&#xD;
          5. Body weight &lt;60 Kg.&#xD;
&#xD;
          6. Use of strong Cytochrome P450 3A inhibitors (e.g., ketoconazole, itraconazole,&#xD;
             posaconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir,&#xD;
             indinavir, boceprevir, telaprevir, telithromycin and conivaptan) or inducers (e.g.,&#xD;
             rifampin, carbamazepine, St. John's Wort and phenytoin).&#xD;
&#xD;
          7. On treatment with any oral anticoagulant (vitamin K antagonists, dabigatran,&#xD;
             rivaroxaban, apixaban, edoxaban).&#xD;
&#xD;
          8. On treatment with any antiplatelet agent other than aspirin, prasugrel and ticagrelor&#xD;
             in the past 14 days.&#xD;
&#xD;
          9. Creatinine clearance &lt;30 mL/minute.&#xD;
&#xD;
         10. Platelet count &lt;80x106/mL&#xD;
&#xD;
         11. Hemoglobin &lt;10g/dL&#xD;
&#xD;
         12. Hemodynamic instability&#xD;
&#xD;
         13. Pregnant females&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominick J Angiolillo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida College of Medicine-Jacksonville</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 8, 2015</study_first_submitted>
  <study_first_submitted_qc>September 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2015</study_first_posted>
  <results_first_submitted>August 10, 2020</results_first_submitted>
  <results_first_submitted_qc>August 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 25, 2020</results_first_posted>
  <last_update_submitted>September 15, 2020</last_update_submitted>
  <last_update_submitted_qc>September 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prasugrel</keyword>
  <keyword>ticagrelor</keyword>
  <keyword>vorapaxar</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
    <mesh_term>Vorapaxar</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 30, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT02545933/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT02545933/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>DAPT Plus Vorapaxar</title>
          <description>Aspirin plus prasugrel or ticagrelor plus vorapaxar 2.5mg od&#xD;
Prasugrel: Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)&#xD;
Vorapaxar: Vorapaxar will be administered at the dose of 2.5mg once daily&#xD;
Aspirin: Aspirin will be administered at the dose of 81mg once daily&#xD;
Ticagrelor: Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)</description>
        </group>
        <group group_id="P2">
          <title>Prasugrel/Ticagrelor Plus Vorapaxar</title>
          <description>Prasugrel or ticagrelor plus vorapaxar 2.5mg od&#xD;
Prasugrel: Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)&#xD;
Vorapaxar: Vorapaxar will be administered at the dose of 2.5mg once daily&#xD;
Ticagrelor: Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)</description>
        </group>
        <group group_id="P3">
          <title>DAPT</title>
          <description>Aspirin in addition to prasugrel or ticagrelor&#xD;
Prasugrel: Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)&#xD;
Aspirin: Aspirin will be administered at the dose of 81mg once daily&#xD;
Ticagrelor: Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DAPT Plus Vorapaxar</title>
          <description>Aspirin plus prasugrel or ticagrelor plus vorapaxar 2.5mg od&#xD;
Prasugrel: Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)&#xD;
Vorapaxar: Vorapaxar will be administered at the dose of 2.5mg once daily&#xD;
Aspirin: Aspirin will be administered at the dose of 81mg once daily&#xD;
Ticagrelor: Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)</description>
        </group>
        <group group_id="B2">
          <title>Prasugrel/Ticagrelor Plus Vorapaxar</title>
          <description>Prasugrel or ticagrelor plus vorapaxar 2.5mg od&#xD;
Prasugrel: Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)&#xD;
Vorapaxar: Vorapaxar will be administered at the dose of 2.5mg once daily&#xD;
Ticagrelor: Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)</description>
        </group>
        <group group_id="B3">
          <title>DAPT</title>
          <description>Aspirin in addition to prasugrel or ticagrelor&#xD;
Prasugrel: Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)&#xD;
Aspirin: Aspirin will be administered at the dose of 81mg once daily&#xD;
Ticagrelor: Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
            <count group_id="B2" value="43"/>
            <count group_id="B3" value="43"/>
            <count group_id="B4" value="130"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" spread="9"/>
                    <measurement group_id="B2" value="56" spread="9"/>
                    <measurement group_id="B3" value="56" spread="10"/>
                    <measurement group_id="B4" value="56" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes mellitus</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximal Platelet Aggregation</title>
        <description>The primary end point of our study is the comparison of maximal platelet aggregation measured by light transmittance aggregometry using CAT (collagen-ADP-TRAP) between DAPT and DAPT plus vorapaxar after 30 days of treatment.</description>
        <time_frame>30 days</time_frame>
        <population>130 patients were randomized and exposed to at least one dose of study medication (triple therapy, n=44; dual therapy, n= 43; DAPT, n=43). Of these, 115 patients (triple therapy, n=37; dual therapy, n= 39; DAPT, n=39) had valid primary endpoint data</population>
        <group_list>
          <group group_id="O1">
            <title>DAPT Plus Vorapaxar</title>
            <description>Aspirin plus prasugrel or ticagrelor plus vorapaxar 2.5mg od&#xD;
Prasugrel: Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)&#xD;
Vorapaxar: Vorapaxar will be administered at the dose of 2.5mg once daily&#xD;
Aspirin: Aspirin will be administered at the dose of 81mg once daily&#xD;
Ticagrelor: Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel/Ticagrelor Plus Vorapaxar</title>
            <description>Prasugrel or ticagrelor plus vorapaxar 2.5mg od&#xD;
Prasugrel: Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)&#xD;
Vorapaxar: Vorapaxar will be administered at the dose of 2.5mg once daily&#xD;
Ticagrelor: Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)</description>
          </group>
          <group group_id="O3">
            <title>DAPT</title>
            <description>Aspirin in addition to prasugrel or ticagrelor&#xD;
Prasugrel: Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)&#xD;
Aspirin: Aspirin will be administered at the dose of 81mg once daily&#xD;
Ticagrelor: Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Maximal Platelet Aggregation</title>
          <description>The primary end point of our study is the comparison of maximal platelet aggregation measured by light transmittance aggregometry using CAT (collagen-ADP-TRAP) between DAPT and DAPT plus vorapaxar after 30 days of treatment.</description>
          <population>130 patients were randomized and exposed to at least one dose of study medication (triple therapy, n=44; dual therapy, n= 43; DAPT, n=43). Of these, 115 patients (triple therapy, n=37; dual therapy, n= 39; DAPT, n=39) had valid primary endpoint data</population>
          <units>percent aggregation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" spread="21"/>
                    <measurement group_id="O2" value="64" spread="20"/>
                    <measurement group_id="O3" value="74" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>We hypothesized that adjunctive vorapaxar would result in a significant reduction of CAT-induced platelet aggregation. Assuming a 10% absolute reduction in CAT-induced maximal platelet aggregation with a common standard deviation of 13%, 37 patients per group with valid primary endpoint data were required to detect a significant difference with a 90% power and 2-sided alpha=0.05.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>ANOVA</method>
            <param_type>least square mean difference</param_type>
            <param_value>27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>19</ci_lower_limit>
            <ci_upper_limit>34</ci_upper_limit>
            <estimate_desc>DAPT group vs DAPT plus vorapaxar group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Duration of the study (30 days)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>DAPT Plus Vorapaxar</title>
          <description>Aspirin plus prasugrel or ticagrelor plus vorapaxar 2.5mg od&#xD;
Prasugrel: Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)&#xD;
Vorapaxar: Vorapaxar will be administered at the dose of 2.5mg once daily&#xD;
Aspirin: Aspirin will be administered at the dose of 81mg once daily&#xD;
Ticagrelor: Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)</description>
        </group>
        <group group_id="E2">
          <title>Prasugrel/Ticagrelor Plus Vorapaxar</title>
          <description>Prasugrel or ticagrelor plus vorapaxar 2.5mg od&#xD;
Prasugrel: Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)&#xD;
Vorapaxar: Vorapaxar will be administered at the dose of 2.5mg once daily&#xD;
Ticagrelor: Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)</description>
        </group>
        <group group_id="E3">
          <title>DAPT</title>
          <description>Aspirin in addition to prasugrel or ticagrelor&#xD;
Prasugrel: Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)&#xD;
Aspirin: Aspirin will be administered at the dose of 81mg once daily&#xD;
Ticagrelor: Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>BARC 1 bleeding</sub_title>
                <description>BARC (Bleeding Academic Research Consortium) 1 bleeding</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Dominick Angiolillo</name_or_title>
      <organization>University of Florida</organization>
      <phone>9042443378</phone>
      <email>dominick.angiolillo@jax.ufl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

